Mark Ubert Joins Clinipace Worldwide as Chief Financial Officer

MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global digital contract research organization (dCRO), today announced the addition of Mark Ubert as Chief Financial Officer. In this role, Mark leads all aspects of the company's financial operations including accounting, financial reporting, treasury, and tax teams. He brings more than 25 years of experience in various finance and accounting leadership roles, including more than 15 years in CFO-level positions in the life sciences and healthcare industries.

Mark's professional career began in the public accounting industry, where he was with KPMG and Ernst & Young. Subsequently, he has held various leadership positions with increasing responsibility serving in the capacity of senior financial executive with responsibilities including fundraising, strategic planning, operational support and financial reporting. Some of Mark's key success initiatives were in the areas of domestic and international financial processes and procedures; private equity investor and banker relationships; operational metric tracking and reporting; treasury/cash management functions; and financial reporting and international tax planning. He worked with industry-leading companies such as Omnicare and Quintiles, as well as other mid-tier CROs.

Mark's global experience includes over ten years of on-site financial leadership and operational oversight within multiple countries throughout Europe, South America, and Asia-Pacific. Within that time, Mark was based in Tokyo for five years serving as CFO of Quintiles Transnational Japan K.K.

Mark received a Master of Business Administration (MBA) from the Keller Graduate Program at DeVry University and earned a Bachelor of Business Administration (BBA) from Washburn University. He is a Certified Public Accountant, has received his CGMA certification, and is a member of the American Institute of CPAs.

"Mark's appointment comes at a crucial time in the growth and development of our business," commented Jeff Williams, CEO, Clinipace Worldwide. "With four global acquisitions over the past three years and over 450 employees worldwide, it's important that we continue to build an executive team and management structure that will support our therapeutic, operational, and global expansion goals."

About Clinipace Worldwide

As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms. Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program. We have managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies). Clinipace Worldwide is headquartered in Research Triangle Park, North Carolina with offices in Irvine (CA), Boulder (CO), Overland Park (KS), Zurich (CH), Munich (DE), High Wycombe (UK), Tel-Aviv (IL), Sao Paulo (BR), Buenos Aires (AR), Trivandrum Kerala (IN) and New Delhi (IN). For more information, visit our website at www.clinipace.com.

Contacts